Table 1.
Baseline characteristics pre- and post-matching
| Baseline characteristics a |
RADIANT-3 study sample |
A6181111 |
|
|---|---|---|---|
| Pre-match | Post-match | As reported | |
| Median age (years)b |
58.0 |
56.5 |
56.5 |
| Age > 64 years |
27.4 |
26.3 |
26.3 |
| Female |
44.9 |
52.0 |
52.0 |
| WHO or ECOGc performance status of 0 |
68.8d |
55.0 |
55.0 |
| Time since diagnosis ≥3 years |
46.7 |
48.0 |
48.0 |
| Number of disease sites |
|
|
|
| 1 |
28.2 |
31.4 |
31.4 |
| 2 |
36.8 |
33.7 |
33.7 |
| ≥3 |
35.0 |
34.9 |
34.9 |
| Presence of distant metastases |
96.2 |
94.7 |
94.7 |
| Previous somatostatin analogues |
49.2d |
36.3 |
36.3 |
| Previous systemic chemotherapy | 48.7d | 69.0 | 69.0 |
Notes:
aReported as percentages, unless otherwise noted.
bFor A6181111, 56.5 is the midpoint between reported medians on the active (56) and placebo (57) arms.
cAn ECOG performance status of 0 was equated to a WHO performance status of 0.
dP < 0.05 for comparison vs. A6181111.